A 35-year-old female with a history of mild asthma presents to the pharmacy. She has been using albuterol inhaler as needed but reports two recent episodes of worsening symptoms requiring oral corticosteroids. She is currently not on any inhaled corticosteroids. She has no known drug allergies and is insured with moderate copayments. She expresses concern about frequent steroid use and wants to avoid exacerbations.

Based on the BATURA trial findings, which of the following is the most appropriate recommendation for this patient to reduce her risk of severe asthma exacerbations?

A 50-year-old male with mild asthma controlled on as-needed albuterol presents for medication counseling. He has a history of hypertension and type 2 diabetes. He is concerned about the side effects of systemic corticosteroids he has needed during past exacerbations. He currently uses albuterol inhaler only and is interested in options to minimize steroid exposure.

What key benefit of as-needed albuterol-budesonide should the pharmacist emphasize to this patient based on the BATURA trial results?

A 28-year-old male with mild asthma has been prescribed as-needed albuterol-budesonide inhaler following recent exacerbations. He is a smoker and has irregular medication adherence due to his work schedule. He asks the pharmacist how this inhaler differs from his previous albuterol inhaler and how to use it effectively.

What is the best counseling point the pharmacist should provide regarding the use of as-needed albuterol-budesonide inhaler based on the BATURA trial findings?